174 related articles for article (PubMed ID: 17292610)
1. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
Kainuma M; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
[TBL] [Abstract][Full Text] [Related]
2. 5Alpha-bile alcohols function as farnesoid X receptor antagonists.
Nishimaki-Mogami T; Kawahara Y; Tamehiro N; Yoshida T; Inoue K; Ohno Y; Nagao T; Une M
Biochem Biophys Res Commun; 2006 Jan; 339(1):386-91. PubMed ID: 16300737
[TBL] [Abstract][Full Text] [Related]
3. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB
Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460
[TBL] [Abstract][Full Text] [Related]
4. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp.
Nam SJ; Ko H; Shin M; Ham J; Chin J; Kim Y; Kim H; Shin K; Choi H; Kang H
Bioorg Med Chem Lett; 2006 Oct; 16(20):5398-402. PubMed ID: 16905319
[TBL] [Abstract][Full Text] [Related]
6. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
[TBL] [Abstract][Full Text] [Related]
7. Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity.
Nam SJ; Ko H; Ju MK; Hwang H; Chin J; Ham J; Lee B; Lee J; Won DH; Choi H; Ko J; Shin K; Oh T; Kim S; Rho JR; Kang H
J Nat Prod; 2007 Nov; 70(11):1691-5. PubMed ID: 17988093
[TBL] [Abstract][Full Text] [Related]
8. FXR: a promising target for the metabolic syndrome?
Cariou B; Staels B
Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
MartÃnez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
10. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
Honorio KM; Garratt RC; Andricopulo AD
Bioorg Med Chem Lett; 2005 Jun; 15(12):3119-25. PubMed ID: 15893927
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.
Zhang T; Zhou JH; Shi LW; Zhu RX; Chen MB
Bioorg Med Chem Lett; 2007 Apr; 17(8):2156-60. PubMed ID: 17307356
[TBL] [Abstract][Full Text] [Related]
13. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
[TBL] [Abstract][Full Text] [Related]
14. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
15. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand.
Takahashi M; Kanayama T; Yashiro T; Kondo H; Murase T; Hase T; Tokimitsu I; Nishikawa J; Sato R
Biochem Biophys Res Commun; 2008 Aug; 372(3):395-9. PubMed ID: 18457666
[TBL] [Abstract][Full Text] [Related]
16. Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
Lin HR; Abraham DJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4178-83. PubMed ID: 16784849
[TBL] [Abstract][Full Text] [Related]
17. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
Cariou B
Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.
Huang H; Si P; Wang L; Xu Y; Xu X; Zhu J; Jiang H; Li W; Chen L; Li J
ChemMedChem; 2015 Jul; 10(7):1184-99. PubMed ID: 25982493
[TBL] [Abstract][Full Text] [Related]
19. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
Swales KE; Korbonits M; Carpenter R; Walsh DT; Warner TD; Bishop-Bailey D
Cancer Res; 2006 Oct; 66(20):10120-6. PubMed ID: 17047076
[TBL] [Abstract][Full Text] [Related]
20. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
